Related Experiment Video

Updated: Jun 22, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Pharmacotherapy of coronary atherosclerosis

Aloke V Finn1, Miranda C A Kramer, Marc Vorpahl

  • 1Emory University School of Medicine, Atlanta, Georgia, USA.

Expert Opinion on Pharmacotherapy
|June 17, 2009
PubMed

Insights

Statins are limited in preventing myocardial infarction, highlighting the need for new treatments targeting atherosclerosis plaque complexity beyond lipid lowering. Future therapies require advanced imaging and pharmacologic agents to modify plaque characteristics.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Medical Imaging

Background:

  • Atherosclerosis remains a leading cause of myocardial infarction, with statins proving ineffective for many patients.
  • Current treatments focusing solely on lipid lowering do not fully address the complex pathology of atherosclerosis.
  • Limitations in characterizing atherosclerotic lesions hinder personalized risk assessment and treatment strategies.

Purpose of the Study:

  • To highlight the limitations of current atherosclerosis pharmacotherapy and imaging.
  • To emphasize the need for novel therapeutic targets beyond lipid reduction.
  • To underscore the requirement for advanced methods to characterize plaque histology in vivo.

Main Methods:

  • Review of current pharmacotherapy limitations for atherosclerosis.
  • Analysis of challenges in current medical imaging for plaque characterization.
  • Discussion of critical plaque components requiring therapeutic intervention.

Main Results:

  • Statins are ineffective in preventing myocardial infarction for approximately two-thirds of patients.
  • Existing imaging modalities cannot adequately characterize non-flow limiting lesions.
  • Key plaque features like macrophage foam cells, neoangiogenesis, necrotic core size, and fibrous cap thickness need modification.

Conclusions:

  • Novel pharmacologic agents and refined monitoring are essential for effective atherosclerosis treatment.
  • Targeting specific plaque components is crucial for improving patient outcomes.
  • Advancements in understanding and modifying atherosclerotic plaque are necessary for better prevention of myocardial infarction.

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...